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SUPPLEMENTARY NOTES
ABSTRACT
The basis of the proposed research is to investigate a novel idea that some of the underlying cause of brain abnormalities in TSC is due to disruption of the oligodendrocytes and production of the myelin wrapping; this in turn leads to alterations in the neurons and their ability to signal properly to other neurons. Proper communication between the oligodendrocytes and the axons is necessary for normal brain development. The oligodendrocytes receive signals from the axons to initiate myelination and to wrap the axon properly. In turn, the formation of the myelin wrapping allows communication between neurons and refinement of neuronal and brain function during development. Data accumulating from these studies indicate that disruption of TSC in primary rat oligodendrocyte progenitors in vitro alters the differentiation and myelination program in these cells. The altered development of the myelin-producing cells may interfere with the ability of the neurons to develop and function normally.
SUBJECT TERMS
TSC Regulates Oligodendrocyte Differentiation
INTRODUCTION:
Tuberous sclerosis complex (TSC) syndrome causes dysplastic and disorganized overgrowth within many organs including the brain. Most TSC patients exhibit various neurological disorders, however, the underlying mechanisms for these disorders in TSC remain largely unknown. The TSC1-TSC2 (hamartin-tuberin) complex is a critical negative regulator of the mammalian target of rapamycin (mTOR) signaling pathway through its GAP (GTPase-activating protein) activity towards the small G-protein Rheb. Our recent data strongly support the hypothesis that mTOR signaling is essential for differentiation of oligodendrocytes (OLs), the myelin producing cells of the central nervous system (CNS). To date, investigations of TSC syndrome in the CNS have focused on neuronal populations. Based on our new data, we hypothesize that TSC loss of function mutations also result in over-activation of mTOR in OLs leading to abnormal OL numbers and myelination. Dysregulation of mTOR in OLs could have a dramatic effect on neuronal function and could contribute to the neurological phenotypes observed in TSC. In support of this hypothesis, studies are emerging suggesting a role for abnormal myelination in a variety of neurological disorders including autism. Progress: Knockdown of TSC1 has been performed on primary rat OPCs in three separate experiments. In two of three experiments, we established that the knockdown of TSC is optimal at 24-48 hrs with recovery of TSC protein levels apparent by 72 hrs ( Figure 1A ,B). One representative experiment is shown in Figure 1 . In the third experiment, the level of transfection of the siRNA appeared low due to reduced cell viability so knockdown of TSC was not observed. Thus, this experiment was not used for further analysis of targets. Milestone #4 Determine whether knockdown of TSC alters activation of TORC1 and TORC2 targets and whether it alters proliferation or survival of OPCs.
Progress:
Using samples from experiments where we verified knockdown of TSC1, we analyzed phosphorylation of mTORC1 or mTORC2 targets. We found that P/total-S6 was increased at day 2 consistent with TSC acting as an inhibitor of mTORC1 ( Figure  1A ,C). We also observed increased P/Total levels of Akt(ser473), a readout of mTORC2 activity ( Figure 1A,D) . This finding suggests that TSC acts to negatively inhibit both complexes. However, we also note that total levels of Akt are significantly decreased in the TSC knockdown cells which contributes to the increased ratio of P/total Akt levels.
We are unclear at this time how this finding alters our model of TSC function in oligodendrocyte progenitors but will continue to monitor Akt levels in future experiments. Cleaved caspase 3 and Ki67 have not yet been analyzed in the TSC knockdown experiments.
2c. Test effect of siRNA knockdown of TSC1 on mTOR targets involved in OL differentiation and regulated at mRNA level, Id2, Id4, TCF4, MBP, PLP, by qPCR analysis. OPCs will be electroporated, after 24 hr transferred to differentiation media and analyzed at 24, 48, 72 and 96 hr. 8 litters of postnatal day 1-2 rats. Timeframe = months 6-9. Milestone #5 Determine whether knockdown of TSC alters mRNA expression of genes involved in OL differentiation.
These experiments are planned for the next 2 months.
2d. Test effect of siRNA knockdown of TSC1 on mTOR targets involved in OL differentiation and regulated at protein level, Sirt2, beta4 tubulin, MBP, PLP, CNPase, by Western blot analysis. OPCs will be electroporated, after 24 hr transferred to differentiation media and analyzed at 24, 48, 72 and 96 hr. 8 litters of postnatal day 1-2 rats. Timeframe = months 6-9. Milestone #6 Determine whether knockdown of TSC alters proteins induced during OL differentiation and regulated by mTOR.
We have initiated these studies using protein from experiments where we have verified sufficient TSC knockdown in OPCs. Analyses of MBP and Sirt2 protein levels indicate that both MBP an Sirt2 are decreased in TSC knockdown cells compared to control siRNA transfected cells ( Figure 2 ). This result is very surprising and contradicts our model that knocking down TSC will promote oligodendrocyte differentiation and the myelination program. However, what is interesting is there is a significant response of the cells in terms of a differentiation program to knockdown of TSC supporting our hypothesis that TSC actions in the oligodendrocyte lineage may contribute to brain phenotypes in TSC mutations. 5c. Analyze myelination in co-cultures with knockdown of TSC1 in OPCs. Seed OPCs that carry the control or shRNA virus for TSC1. Cultures will be fixed, dehydrated, embedded in epon and semi-thin sections will be obtained and stained with toludine blue on day 7 and day 18. The percentage of myelinated axons and the g-ratio will be determined. 2 litters of prenatal rat pups, 2 litters of postnatal rat pups. Timeframe = months 12-15. Milestone #13 Determine whether knockdown of TSC1 alters amount and thickness of myelin in OPC-DRG co-cultures.
Progress Tasks 4-5:
We have had some difficulty with growing lentiviruses in the laboratory and in infecting OPC cultures to maintain their viability. The standard reagents used for infection are toxic to the OPCs. We are currently consulting with colleagues who are experts in both viral vectors and primary OPC culturing. We have put these experiments as second priority and have focused on the in vivo mouse models as the best functional tests of TSC in oligodendroglia. T and ROSA26 mouse lines, treat with tamoxifen by IP injection (1 mg tamoxifen in 100 µl sunflower oil, daily for 5 days to the nursing dams or pups for postweaning timepoints). We will administer tamoxifen at postnatal days 6-10, 11-15 and 16-20 in initial studies in order to delete mTOR at early, mid-or late stages of differentiation. Brains will be analyzed for LacZ and OL lineage by co-labeling for oligodendroglial markers (PDGFRa and NG2 for progenitors, CC1 for mature OLs). 3 animals per timepoint x 3 timepoints = 9 animals. Timeframe = months 9-15. Milestone #16 Establish Cre-loxP deletion in oligodendroglia.
Progress: Initial analyses of bigenic lines following tamoxifen injection are planned for the next 2-3 months.
Task 7. Test in vivo deletion of TSC1 on OL differentiation and myelination (timeframe 12-24 months).
7a. Test loss of TSC1 using PLP-CreER T -induced recombination in oligodendroglia in corpus callosum. Mate PLP-CreER T and Tsc1 tm1Djk /J mouse lines, treat with tamoxifen by IP injection (1 mg tamoxifen in 100 µl sunflower oil, daily for 5 days to the nursing dams or pups for post-weaning timepoints). We will administer tamoxifen at postnatal days 6-10, 11-15 and 16-20 in order to delete mTOR at early, mid-or late stages of differentiation. We will assess OL lineage by immunolabeling for oligodendroglial markers (PDGFRa and NG2 for progenitors, CC1 for mature OLs) as well as cell proliferation (BrdU or Ki67) and cell death (TUNEL staining). Neurons will be labeled using NeuN. 8 animals per timepoint x 3 timepoints = 24 animals. Timeframe = months 12-18.
Milestone #17 Determine loss of TSC1 on OL differentiation in vivo.
7b. Test loss of TSC1 using PLP-CreER T -induced recombination on myelination in corpus callosum. Mate PLP-CreER T and Tsc1 tm1Djk /J mouse lines, treat with tamoxifen by IP injection (1 mg tamoxifen in 100 µl sunflower oil, daily for 5 days to the nursing dams or pups for post-weaning timepoints). We will administer tamoxifen at postnatal days 6-10, 11-15 and 16-20 in order to delete mTOR at early, mid-or late stages of differentiation. Brains will be fixed, dehydrated, embedded in epon and semi-thin sections will be obtained and stained with toludine blue. The percentage of myelinated axons and the g-ratio will be determined. 8 animals per timepoint x 3 timepoints = 24 animals. Timeframe = months 12-18. Milestone #18 Determine loss of TSC1 on myelination in vivo.
Progress: These analyses are proceeding on schedule for the next period.
KEY RESEARCH ACCOMPLISHMENTS:
• Established siRNA knockdown of TSC1 in primary rat OPCs in vitro.
• Determined that TSC is a critical upstream regulator of mTORC1 and mTORC2 in the oligodendrocyte lineage.
• Found that reduction of TSC1 results in increased activation of both mTORC1 and mTORC2 targets (P-S6 and P-Akt, respectively) in OPCs.
• Reduction of TSC1 in OPCs results in decreased expression of differentiation markers Sirt2 and MBP suggesting inhibition or delay of differentiation.
• Reduction of TSC1 in OPCs reduces total levels of Akt.
REPORTABLE OUTCOMES:
Abstracts and Presentations:
• Wood, T.L., Tyler, W.A., Jain, M.R., Cifelli, S.E., Mahajan, K., Li, Q., Ku, L., Feng, Y, and Li, H. Mechanisms for mTOR regulation of oligodendrocyte differentiation and myelination/remyelination. (2011) Symposium presentationInternational Society for Neurochemistry, Athens, Greece.
CONCLUSION:
Our data obtained to date strongly support our hypothesis that TSC function in oligodendroglia is essential for their normal development and myelination functions. However, our data indicate that how TSC regulates mTOR signaling and the consequences of TSC disruption is more complicated than we originally proposed. Specifically, we anticipated that activation of the mTOR complexes by TSC deletion or reduction would result in accelerated oligodendrocyte differentiation and hypermyelination. Our findings indicate that the reduction in TSC is actually inhibiting oligodendrocyte differentiation. Our current interpretation of these findings is that mTOR complex signaling may be time-dependent and that sustained activation of the complexes inhibits the myelination program. We will continue to test our hypotheses through ongoing proposed studies with a particular focus on the in vivo transgenic mouse models. In vitro, we would like to extend our knockdown analyses to 4-5 days following siRNA transfection to determine if the differentiation is merely delayed and recovers. We also propose to focus on the in vivo deletion of TSC specifically in the oligodendrocyte lineage as proposed in Aim 2 as priority over the in vitro co-culture myelination studies.
"So what?"
Tuberous sclerosis complex (TSC) syndrome causes dysplastic and disorganized overgrowth within many organs including the brain. Most TSC patients exhibit various neurological disorders, however, the underlying mechanisms for these disorders in TSC remain largely unknown. To date, the focus of understanding brain disfunction in TSC has focused on neurons. Based on our published data, we proposed to test the novel hypothesis that critical aspects of neurological dysfunction in TSC are due to disruption of differentiation and the production of myelin from the oligodendroglia. Our findings thus far support our hypothesis that TSC has essential functions in development of oligodendroglia, however, the exact function of TSC upstream of mTOR appears more complicated than we first proposed. These data strongly support continued analysis of TSC in regulation of this lineage.
REFERENCES:
Abstracts: Recent studies revealed that the mammalian target of rapamycin (mTOR) signaling pathway, a major target downstream of Akt, regulates oligodendrocyte differentiation/myelination (1, 2) . The objectives of this study were i) to define the mTOR regulated proteome in differentiating oligodendrocyte progenitor cells (OPCs), and ii) to determine whether mTOR signaling is important for remyelination following a focal demyelinating injury. In order to define the mTOR regulated proteome, we applied an iTRAQ mass spectrometry-based proteomic approach. Among the 978 proteins identified in this study, 328 (34%) exhibited a greater than 20% change (p < 0.05) in control versus rapamycin treated OPCs following 4 days of differentiation in vitro. Interestingly, 197 (20%) proteins were elevated in rapamycin treated cultures, while 131 (13%) proteins were down-regulated by rapamycin. Inhibiting mTOR decreased expression of myelin proteins, proteins involved in cholesterol and fatty acid synthesis, as well as many cytoskeletal proteins, cell signaling components, and nuclear/transcriptional regulators. Of particular interest was the identification of several critical mediators of oligodendrocyte differentiation including the pro-differentiation factors Fyn and Quaking. To address whether mTOR signaling is required for remyelination, we analyzed remyelination following a cortical focal demyelination in adult mice treated with either vehicle or the mTOR inhibitor rapamycin. Analysis of lesions revealed delayed remyelination at 21 days in the rapamycin-treated animals supporting the hypothesis that mTOR signaling is required for both developmental myelination as well as remyelination. P2X receptors are ATP-gated cation channels contributing to diverse physiological mechanisms including pain signalling and inflammatory response. The P2X4 subtype has been shown to be directly involved in microglial activation and central sensitization of nociceptive neurons, making its functional regulation a crucial process in chronic pain pathologies. The P2Y6 receptor is positively coupled to phospholipase C via Gq/11 proteins and is also expressed in microglia, where it plays a pivotal role in the initial response to nerve injury, triggering phagocytosis upon UDP-mediated activation. Interestingly, recent reports have shown that expression of both P2X4 and P2Y6 is upregulated in activated microglia following nerve injury. Here, we show that in primary mouse microglia, activation of P2Y6 modulates P2X4 function as P2Y6 activation by its agonist UDP induced a significant decrease in P2X4-mediated calcium entry. We recently observed that microglial P2X4 channels can dilate into a macropore upon prolonged ATP stimulation; this property was also inhibited by simultaneous activation of P2Y6 as measured via YO-PRO-1 uptake assay. We reproduced this modulation in the Xenopus oocyte expression system, where P2Y6 activation induced a decrease in P2X4 current amplitude, activation and desensitization rates, as well as an inhibition of P2X4 macropore formation. This interaction was blocked by U73122, a phospholipase C inhibitor, but was unaffected by blocking protein kinase C (PKC) with staurosporine. This suggests that the functional modulation of P2X4 relies on the hydrolysis of PI(4,5)P2, a membrane-bound phosphoinositide recently shown to be a direct positive regulator of P2X4 channel function. These data indicate that metabotropic P2Y6 receptors can significantly affect both P2X4 current and macropore dilation, representing a novel cross-talk between purinoceptors in microglia. High extracellular levels of ATP and UDP are observed in conditions of nerve injury, therefore interactions between receptors sensitive to these agonists are critical in regulating pain-inducing microglial responses. Nitric Oxide Synthase III (NOS3, NOS-3, eNOS) has not been formerly characterized in oligodendrocyte, in contrast to the other NOS isoforms. We present converging data of NOS3 expression at the molecular and protein levels in primary culture of oligodendrocytes. NOS3 was detected at the protein level by immunocytochemistry, and at the messenger level by quantitative PCR. We used antibodies from different companies that were strictly specific to NOS3 and did not recognize the other isoforms NOS1 (nNOS) and NOS2 (iNOS), as assessed by Western Blot. Immunostaining for NOS3 was found across species in human, rat and baboon primary oligodendrocyte cultures. NOS3 protein was found restricted to the cytoplasm, in the cell body and the thick processes branching out from the cell body. NOS3 was never present in the flat membrane extensions. NOS3 protein and mRNA were found at any time points during the 3 weeks culture necessary for human oligodendrocytes to regenerate large membranes expressing galactocerebroside, myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein. NOS3 protein was found expressed early in the lineage in bipolar oligodendrocyte progenitors, and its expression was maintained at the mature stage of membrane-bearing human oligodendrocytes in long-term culture up to 2 months. NOS3 was also found in mouse oligospheres derived from E13 cells. NOS3 colocalized with caveolin-1, a protein bound to NOS3 and one of its main regulator in endothelial cells. Inhibition of NOS3 by the specific ligand N-[imino(methylamino)methyl]-Lornithine (L-NMMA) led to a disruption of the organization pattern of MBP and the cytoskeleton component actin, that were accompanied by marked changes in oligodendrocyte arborization. NOS3 appears to be a signaling molecule for the cytoskeleton which is involved in intracellular trafficking, process extension and myelin production in oligodendrocytes. Recent proteomic analysis revealed novel mTOR targets and a more complex picture of mTOR function in differentiating oligodendrocyte progenitor cells (OPCs). To further this analysis and search for direct targets of mTOR during oligodendrocyte differentiation we performed iTRAQ-MS analysis of protein samples isolated following 2d and 4d of differentiation in the presence or absence of rapamycin, an mTOR inhibitor. The changed proteins at 2d of differentiation, either increased or decreased in the presence of rapamycin, were further sorted based on molecular function. Cytoskeletal proteins represented the largest group downregulated by mTOR inhibition consistent with the hypothesis that mTOR regulates morphological complexity at the transition from the late progenitor to the immature oligodendrocyte. Proteins that were upregulated in the presence of rapamycin included those involved in regulating protein translation and translation initiation. As a major function of the mTOR/raptor complex is to positively regulate protein translation, the upregulation of translation factors in the presence of rapamycin suggests that the ability of mTOR signaling to finely tune the expression of specific transcripts via translational control plays a central role in regulating oligodendrocyte differentiation. Ongoing studies are directed towards validating identified targets in the mTOR-regulated proteome and elucidating direct nuclear targets of mTOR necessary for mediating oligodendrocyte differentiation.
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